Neutral
The article discusses the potential for China-originated anti-PD-(L)1/VEGF bispecific antibodies to compete in upcoming Phase III trials. This develop...
Neutral
BioNTech, the company behind the COVID-19 vaccine Comirnaty, is facing a significant revenue decline as demand for its vaccine fades after the pandemi...
Neutral
BioNTech is shifting its focus from COVID-19 vaccines to oncology, leveraging its mRNA technology for individualized cancer therapies. While this pivo...